News

Filter

Current filters:

AmgenSanofi

Sanofi and Regeneron’s Praluent BLA gains priority review from US FDA

26-01-2015

The US Food and Drug Administration has accepted for priority review the Biologics License Application…

alirocumabAmgenBiotechnologyCardio-vascularevolocumabPraluentRegeneron PharmaceuticalsRegulationSanofiUSA

Biologics will complement statins in cholesterol treatment space, says GlobalData

Biologics will complement statins in cholesterol treatment space, says GlobalData

11-11-2014

Biologics will play an influential role in shaping the future of cardiovascular drug treatment, in particular…

alirocumabAmgenCardio-vascularevolocumabMarkets & MarketingPharmaceuticalRegeneronSanofiUSA

This week’s third quarter pharma financial results in brief

This week’s third quarter pharma financial results in brief

31-10-2014

Several pharma, biotech and generics makers announced their third quarter results this week. Here are…

AmgenBayerDr Reddy's LaboratoriesFinancialGilead SciencesIpsenMerck & CoNicOxNovartisNovo NordiskPfizerRecordatiSanofiShireTeva

Amgen sues Sanofi and Regeneron over alleged patent infringement

19-10-2014

USA-based Amgen has filed a law suit in the US District Court of Delaware against French pharma major…

alirocumabAmgenBiotechnologyCardio-vascularevolocumabLegalPatentsRegeneron PharmaceuticalsSanofiUSA

Fast growth forecast for China’s colorectal cancer market

Fast growth forecast for China’s colorectal cancer market

13-12-2013

From 2012 to 2017, the colorectal cancer therapy market in China will grow at an annual rate of 9%, from…

AmgenAsia-PacificBayerIndiaMarkets & MarketingOncologyPharmaceuticalSanofiStivargaVectibixZaltrap

Highlights of presentations planned for ASCO meeting

17-05-2012

Ahead of the annual American Society of Clinical Oncology (ASCO) meeting which takes place in Chicago…

AmgenBayerBiotechnologyBristol-Myers SquibbOncologyPharmaceuticalResearchSanofi

Back to top